Related Experiment Videos
Inflammatory bowel disease: where are the frontiers?
The Medical Clinics of North America
|November 1, 1980
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Inflammatory bowel disease. The case for an infectious etiology.
The Medical clinics of North America·1994
Use of rifabutin in treatment of systemic Mycobacterium paratuberculosis infection in mice.
Antimicrobial agents and chemotherapy·1993
The use of antimycobacterial agents in Crohn's disease.
Journal of clinical gastroenterology·1992
Implications of antibodies to pyruvylated glucose in healthy populations for mycobacterioses and other infectious diseases.
Journal of clinical microbiology·1990
Mycobacterium paratuberculosis infection in a colony of stumptail macaques (Macaca arctoides).
The Journal of infectious diseases·1987
Experimental disease in infant goats induced by a Mycobacterium isolated from a patient with Crohn's disease. A preliminary report.
Digestive diseases and sciences·1986
Care Transitions and Value-Based Payment Models in the United States.
The Medical clinics of North America·2026
Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.
The Medical clinics of North America·2026
Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.
The Medical clinics of North America·2026
Social Determinants of Health: Unique Considerations in Transitions of Care.
The Medical clinics of North America·2026
Geriatric Care Transitions: Addressing the Complex Needs of Older Adults.
The Medical clinics of North America·2026
Using Implementation Science to Understand the Pediatric to Adult Healthcare Transition.
The Medical clinics of North America·2026
Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.
Case reports in dermatological medicine·2026
Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.
Frontiers in endocrinology·2026
Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.
Kidney diseases (Basel, Switzerland)·2026
Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.
Frontiers in cell and developmental biology·2026